Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    "Gastro-enteropancreatic neuroendocrine tumor"
Show Display Options
RSS Create an RSS feed from your search for:
"Gastro-enteropancreatic neuroendocrine tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Intervention: Drug: Famitinib
2 Terminated Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test);   Drug: Indium-111-Octreoscan (standard test)
3 Recruiting 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Condition: Gastro-entero-pancreatic Neuroendocrine Tumors
Interventions: Drug: Capecitabine;   Drug: Lu-PRRT;   Drug: SS-LAR
4 Completed TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Condition: Patients With Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68-Ga-DOTANOC
5 Recruiting Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
Condition: Gastroenteropancreatic Neuroendocrine Tumours
6 Not yet recruiting [68 Ga]-DOTANOC PET/CT in GEP-NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: [68Ga]-DOTANOC PET/CT
7 Recruiting Community-based Neuroendocrine Tumor (NET) Research Study
Condition: Gastroenteropancreatic Neuroendocrine Tumors
8 Active, not recruiting Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Lanreotide Autogel 120 mg;   Drug: Temozolomide (TMZ)
9 Not yet recruiting Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in GEP NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 177Lu-OPS201
10 Completed 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68Ga-OPS202
11 Active, not recruiting Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Gastro Entero Pancreatic Neuroendocrine Tumors
Interventions: Drug: 28 GBq 177Lu-DOTATATE;   Drug: 22 GBq 177Lu-DOTATATE
12 Completed Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus;   Drug: Everolimus followed by Pasireotide LAR + Everolimus
13 Withdrawn Pasireotide Treatment for Neuroendocrine Tumor
Condition: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Drug: Pasireotide;   Drug: Diazoxide
14 Recruiting Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
15 Recruiting 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: Intravenous injection of 177Lu-octreotate
16 Active, not recruiting The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor;   Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
17 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
18 Enrolling by invitation Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan
Condition: This Study Plans to Include 600 GEP-NET Patients.

Indicates status has not been verified in more than two years